Table 4.
Groups | Weekly FBG level (mg/dl) |
|||
---|---|---|---|---|
Initial | 1st | 2nd | 3rd | |
NOC | 96.40 ± 0.67 | 97.80 ± 0.97 | 97.60 ± 0.51 | 96.80 ± 0.86 |
NC | 357.00 ± 23.01 Ac | 374.00 ± 27.72 Ac | 393.60 ± 29.61 Ac | 394.80 ± 26.19 Ac |
GL5 | 323.60 ± 45.47 Ac | 223.00 ± 42.09 Aa | 158.20 ± 28.31 Bc | 86.40 ± 5.99 Bc |
RELE100 | 320.40 ± 25.80Ac | 312.60 ± 54.41A1 | 232.40 ± 40.26 AaBb | 205.20 ± 31.47 AcBc |
RELE200 | 307.60 ± 33.26Ac | 288.00 ± 35.25Aa | 197.00 ± 21.86 Bc | 188.00 ± 20.40 Bc |
RELE400 | 315.00 ± 35.12Ac | 256.60 ± 29.49 Aa | 197.20 ± 22.69 Bc | 179.60 ± 15.14Bc |
Each value represents mean ± S.E.M; n = 6; Analysis was performed by one way ANOVA; Acompared to normal control; Bcompared to negative control; number followed by RELE and GL indicates dose in mg/kg; ap < 0.05; bp < 0.01; cp < 0.001.
Abbreviations: NOC, normal control; NC, negative control; GL, glibenclamide; RELE, Rubus erlangeri leaf extract.